Technology Networks recently spoke with Stephen Williams, CMO at biotechnology company SomaLogic, to learn more about research progress in the proteomics space and the technology that has enabled it.
Technology Networks spoke with Erik Allen, Vice President and General Manager, Specimen Management for BD, to learn more about the advantages of capillary collection and the importance of making diagnostic testing more convenient and comfortable for patients.Read More
Technology Networks recently spoke with LifeArc’s CEO Melanie Lee, PhD, CBE. Melanie elaborates on LifeArc's mission, discusses the importance of bridging the gap between "bench" and "bedside", and highlights how genomics can help drive earlier intervention.
Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex, a lead drug candidate that treats non-small cell lung cancer, and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.Read More
Technology Networks spoke with GenapSys to learn more about the sequencer which is "100x smaller and less expensive than legacy high-throughput sequencers" and how it can be applied to study the Coronavirus.Read More
The highly complex process of whole genome sequencing comes with a high cost of error. One pipetting or mixing mistake can lead to costly errors downstream. When working with multiple samples, error-free sample handling and proper mixing becomes even more critical. The first step in the process to prepare the sample for sequencing, library prep, is a vital step that, if not done correctly, can lead to flawed data and costly delays.Read More
Thermo Fisher Scientific and Owlstone Medical have recently entered a collaboration, with the aim of advancing breath diagnostics for the early diagnosis of cancer and other diseases. Dr Max Allsworth, Chief Science Officer, Owlstone Medical, and Dominic Roberts, Product Marketing Manager, Orbitrap GC-MS, Thermo Fisher Scientific tell us more about the collaboration and the advantages that breath biopsies can bring to disease detection.Read More
Many clinical trials fail due to lack of efficacy. But while some of this may be due to poor target selection during the drug discovery process, it’s becoming increasingly clear that only certain patients respond to treatments. So how exactly does precision medicine increase the likelihood of success in clinical trials?Read More
We recently spoke to Luca Quagliata, Ph.D., Global Head of Medical Affairs for Clinical NGS and Oncology at Thermo Fisher Scientific, to discuss some of the barriers preventing full adoption of NGS-based genomic testing in hospitals, and learn more about a solution that can help to address these.Read More